(AOF) – Samsung Biologics has denied press reports according to which the Korean group has approached the American pharmaceutical company Biogen for a possible takeover. The Korea Economic Daily newspaper on Wednesday revealed a potential deal at $ 42 billion, which would have made it the largest acquisition for a Korean group outside its borders. Samsung Biologics called these claims “false”, without providing further explanation.
AOF – LEARN MORE
Boost for French pharmacy
At the end of a recent CSIS, the French authorities announced an unprecedented amount of credits (7 billion euros): 1.5 billion for university hospital research, 2 billion for investment in health via bpi France , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenses reimbursed by Medicare will be 2.4%, which should generate growth of at least 0.5% in laboratory turnover,
Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the actual benefit is sufficient.